{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T20:31:56Z","timestamp":1783369916607,"version":"3.54.6"},"reference-count":185,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T00:00:00Z","timestamp":1684368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:p>Increased human activities around the globe and the rapid development of once rural regions have increased the probability of contact between humans and wild animals. A majority of bunyaviruses are of zoonotic origin, and outbreaks may result in the substantial loss of lives, economy contraction, and social instability. Many bunyaviruses require manipulation in the highest levels of biocontainment, such as Biosafety Level 4 (BSL-4) laboratories, and the scarcity of this resource has limited the development speed of vaccines for these pathogens. Meanwhile, new technologies have been created, and used to innovate vaccines, like the mRNA vaccine platform and bioinformatics-based antigen design. Here, we summarize current vaccine developments for three different bunyaviruses requiring work in the highest levels of biocontainment: Crimean-Congo Hemorrhagic Fever Virus (CCHFV), Rift Valley Fever Virus (RVFV), and Hantaan virus (HTNV), and provide perspectives and potential future directions that can be further explored to advance specific vaccines for humans and livestock.<\/jats:p>","DOI":"10.3389\/fcimb.2023.1174030","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:23:07Z","timestamp":1684394587000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Advances and perspectives in the development of vaccines against highly pathogenic bunyaviruses"],"prefix":"10.3389","volume":"13","author":[{"given":"Tong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00705-019-04253-6","article-title":"Taxonomy of the order bunyavirales: update 2019","volume":"164","author":"Abudurexiti","year":"2019","journal-title":"Arch. Virol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1099\/vir.0.81175-0","article-title":"Presence of broadly reactive and group-specific neutralizing epitopes on newly described isolates of Crimean-Congo hemorrhagic fever virus","volume":"86","author":"Ahmed","year":"2005","journal-title":"J. Gen. Virol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3390\/vaccines7030115","article-title":"Immunological analysis of a CCHFV mRNA vaccine candidate in mouse models","volume":"7","author":"Aligholipour Farzani","year":"2019","journal-title":"Vaccines (Basel)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"237","DOI":"10.20944\/preprints201901.0317.v1","article-title":"Bovine herpesvirus type 4 (BoHV-4) vector delivering nucleocapsid protein of Crimean-Congo hemorrhagic fever virus induces comparable protective immunity against lethal challenge in IFN\u03b1\/\u03b2\/\u03b3R-\/- mice models","volume":"11","author":"Aligholipour Farzani","year":"2019","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/v11010075","article-title":"Co-Delivery effect of CD24 on the immunogenicity and lethal challenge protection of a DNA vector expressing nucleocapsid protein of Crimean Congo hemorrhagic fever virus","volume":"11","author":"Aligholipour Farzani","year":"2019","journal-title":"Viruses"},{"key":"B6","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1177\/10406387211015294","article-title":"Vaccination with rift valley fever virus live attenuated vaccine strain smithburn caused meningoencephalitis in alpacas","volume":"33","author":"Anthony","year":"2021","journal-title":"J. Vet. Diagn. Invest."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/JVI.01568-21","article-title":"Nucleoside-modified mRNA vaccines protect IFNAR mice against Crimean Congo hemorrhagic fever virus infection","volume":"96","author":"Appelberg","year":"2021","journal-title":"J. Virol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vetimm.2018.01.001","article-title":"Expression of cytokines following vaccination of goats with a recombinant capripoxvirus vaccine expressing rift valley fever virus proteins","volume":"197","author":"Ayari-Fakhfakh","year":"2018","journal-title":"Vet. Immunol. Immunopathol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.antiviral.2013.07.006","article-title":"Crimean-Congo Hemorrhagic fever: history, epidemiology, pathogenesis, clinical syndrome and genetic diversity","volume":"100","author":"Bente","year":"2013","journal-title":"Antiviral Res."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2021.e08161","article-title":"Development of a protective inactivated vaccine against Crimean-Congo hemorrhagic fever infection","volume":"7","author":"Berber","year":"2021","journal-title":"Heliyon"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000725","article-title":"Vaccination with DNA plasmids expressing gn coupled to C3d or alphavirus replicons expressing gn protects mice against rift valley fever virus","volume":"4","author":"Bhardwaj","year":"2010","journal-title":"PloS Negl. Trop. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.virol.2008.05.033","article-title":"RNA Polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent rift valley fever viruses","volume":"378","author":"Billecocq","year":"2008","journal-title":"Virology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J. Virol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1128\/JVI.02095-06","article-title":"Complete genome analysis of 33 ecologically and biologically diverse rift valley fever virus strains reveals widespread virus movement and low genetic diversity due to recent common ancestry","volume":"81","author":"Bird","year":"2007","journal-title":"J. Virol."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.875539","article-title":"Identification of single amino acid changes in the rift valley fever virus polymerase core domain contributing to virus attenuation","volume":"12","author":"Borrego","year":"2022","journal-title":"Front. In Cell. Infect. Microbiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.antiviral.2014.05.020","article-title":"Efficacy assessment of an MVA vectored rift valley fever vaccine in lambs","volume":"108","author":"Busquets","year":"2014","journal-title":"Antiviral Res."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091516","article-title":"A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model","volume":"9","author":"Buttigieg","year":"2014","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41541-020-00218-y","article-title":"A protective bivalent vaccine against rift valley fever and bluetongue","volume":"5","author":"Calvo-Pinilla","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1111\/tbed.14415","article-title":"Safety study of rift valley fever human vaccine candidate (DDVax) in mosquitoes","volume":"69","author":"Campbell","year":"2022","journal-title":"Transbound Emerg. Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen-directed attenuation of rift valley fever virus as a method for vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J. Gen. Virol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1016\/S0264-410X(99)00057-2","article-title":"Antibody responses in humans to an inactivated hantavirus vaccine (Hantavax)","volume":"17","author":"Cho","year":"1999","journal-title":"Vaccine"},{"key":"B22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1159\/000067925","article-title":"Review of an inactivated vaccine against hantaviruses","volume":"45","author":"Cho","year":"2002","journal-title":"Intervirology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00860","article-title":"A DNA vaccine encoding the gn ectodomain of rift valley fever virus protects mice via a humoral response decreased by DEC205 targeting","volume":"10","author":"Chrun","year":"2019","journal-title":"Front. Immunol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.648077","article-title":"Differential cell line susceptibility to Crimean-Congo hemorrhagic fever virus","volume":"11","author":"Dai","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/tmi.12108","article-title":"Tempering the risk: rift valley fever and bioterrorism","volume":"18","author":"Dar","year":"2013","journal-title":"Trop. Med. Int. Health"},{"key":"B26","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/path.1700340418","article-title":"Enzootic hepatitis or rift valley fever. an undescribed virus disease of sheep cattle and man from east africa","volume":"34","author":"Daubney","year":"1931","journal-title":"J. Pathol. Bacteriol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1016\/j.vaccine.2009.12.062","article-title":"Rift valley fever virus subunit vaccines confer complete protection against a lethal virus challenge","volume":"28","author":"de Boer","year":"2010","journal-title":"Vaccine"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1073\/pnas.1217780110","article-title":"Crystal structure of glycoprotein c from rift valley fever virus","volume":"110","author":"Dessau","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1099\/jmm.0.000897","article-title":"Incorporation of CD40 ligand or granulocyte-macrophage colony stimulating factor into hantaan virus (HTNV) virus-like particles significantly enhances the long-term immunity potency against HTNV infection","volume":"68","author":"Dong","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1080\/21645515.2015.1078045","article-title":"A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease","volume":"12","author":"Dowall","year":"2016","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156637","article-title":"Protective effects of a modified vaccinia Ankara-based vaccine candidate against Crimean-Congo haemorrhagic fever virus require both cellular and humoral responses","volume":"11","author":"Dowall","year":"2016","journal-title":"PloS One"},{"key":"B32","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1007\/s13205-020-2076-y","article-title":"Chitosan and chitosan nanoparticles as adjuvant in local rift valley fever inactivated vaccine","volume":"10","author":"El-Sissi","year":"2020","journal-title":"3 Biotech."},{"key":"B33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/vaccines5030029","article-title":"Current status of rift valley fever vaccine development","volume":"5","author":"Faburay","year":"2017","journal-title":"Vaccines"},{"key":"B34","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1089\/vbz.2014.1650","article-title":"A glycoprotein subunit vaccine elicits a strong rift valley fever virus neutralizing antibody response in sheep","volume":"14","author":"Faburay","year":"2014","journal-title":"Vector Borne Zoonotic Dis. (Larchmont N.Y.)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"27719","DOI":"10.1038\/srep27719","article-title":"A recombinant rift valley fever virus glycoprotein subunit vaccine confers full protection against rift valley fever challenge in sheep","volume":"6","author":"Faburay","year":"2016","journal-title":"Sci. Rep."},{"key":"B36","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in COVID-19 mRNA vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.medmal.2019.09.005","article-title":"Crimean-Congo Hemorrhagic fever: an update","volume":"49","author":"Fill\u00e2tre","year":"2019","journal-title":"Med. Mal Infect."},{"key":"B38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.iy.08.040190.001511","article-title":"Lymphokine control of in vivo immunoglobulin isotype selection","volume":"8","author":"Finkelman","year":"1990","journal-title":"Annu. Rev. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/156652405774962335","article-title":"Crimean-Congo Hemorrhagic fever virus","volume":"5","author":"Flick","year":"2005","journal-title":"Curr. Mol. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.vaccine.2014.02.043","article-title":"Phase II randomized, double-blinded comparison of a single high dose (5\u00d710(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1\u00d710(8) TCID50) in healthy vaccinia-na\u00efve individuals","volume":"32","author":"Frey","year":"2014","journal-title":"Vaccine"},{"key":"B41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41541-019-0155-z","article-title":"A single dose of a vesicular stomatitis virus-based influenza vaccine confers rapid protection against H5 viruses from different clades","volume":"5","author":"Furuyama","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B42","doi-asserted-by":"publisher","first-page":"922","DOI":"10.14202\/vetworld.2014.922-928","article-title":"Tracing the antibody mediated acquired immunity by foot and mouth disease and rift valley fever combined vaccine in pregnant ewes and their lambs","volume":"7","author":"Gamal","year":"2014","journal-title":"Vet. World"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005908","article-title":"And death in two lethal mouse models","volume":"11","author":"Garrison","year":"2017","journal-title":"PloS Negl. Trop. Dis."},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/v11070590","article-title":"Animal models for Crimean-Congo hemorrhagic fever human disease","volume":"11","author":"Garrison","year":"2019","journal-title":"Viruses"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3973","DOI":"10.1016\/j.vaccine.2005.02.025","article-title":"A hantavirus nucleocapsid protein segment exposed on hepatitis b virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies","volume":"23","author":"Geldmacher","year":"2005","journal-title":"Vaccine"},{"key":"B46","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.virol.2004.02.022","article-title":"An amino-terminal segment of hantavirus nucleocapsid protein presented on hepatitis b virus core particles induces a strong and highly cross-reactive antibody response in mice","volume":"323","author":"Geldmacher","year":"2004","journal-title":"Virology"},{"key":"B47","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1128\/CVI.05352-11","article-title":"Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus","volume":"18","author":"Ghiasi","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw9535","article-title":"GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection","volume":"5","author":"Golden","year":"2019","journal-title":"Sci. Adv."},{"key":"B49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.antiviral.2013.03.009","article-title":"Post-exposure vaccination with MP-12 lacking NSs protects mice against lethal rift valley fever virus challenge","volume":"98","author":"Gowen","year":"2013","journal-title":"Antiviral Res."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0138348","article-title":"Open-label, controlled phase II study to evaluate safety and immunogenicity of MVA smallpox vaccine (IMVAMUNE) in 18-40 year old subjects with diagnosed atopic dermatitis","volume":"10","author":"Greenberg","year":"2015","journal-title":"PloS One"},{"key":"B51","doi-asserted-by":"publisher","first-page":"142919","DOI":"10.1016\/j.scitotenv.2020.142919","article-title":"The Berlin principles on one health - bridging global health and conservation","volume":"764","author":"Gruetzmacher","year":"2021","journal-title":"Sci. Total Environ."},{"key":"B52","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41564-018-0141-7","article-title":"A cynomolgus macaque model for Crimean-Congo haemorrhagic fever","volume":"3","author":"Haddock","year":"2018","journal-title":"Nat. Microbiol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41541-020-0166-9","article-title":"Antigen-specific human T cell responses","volume":"5","author":"Harmon","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41564-020-00815-6","article-title":"A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a cynomolgus macaque model","volume":"6","author":"Hawman","year":"2021","journal-title":"Nat. Microbiol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00871-9","article-title":"Crimean-Congo Haemorrhagic fever virus","author":"Hawman","year":"2023","journal-title":"Nat. Rev. Microbiol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.09.016","article-title":"Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model","author":"Hawman","year":"2022","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e63906","DOI":"10.7554\/eLife.63906","article-title":"Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus","volume":"10","author":"Hawman","year":"2021","journal-title":"Elife"},{"key":"B58","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.it.2023.03.002","article-title":"Leveraging deep learning to improve vaccine design","volume":"44","author":"Hederman","year":"2023","journal-title":"Trends Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02076-16","article-title":"Immunization with DNA plasmids coding for Crimean-Congo hemorrhagic fever virus capsid and envelope proteins and\/or virus-like particles induces protection and survival in challenged mice","volume":"91","author":"Hinkula","year":"2017","journal-title":"J. Virol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1128\/CVI.00182-09","article-title":"A complex adenovirus-vectored vaccine against rift valley fever virus protects mice against lethal infection in the presence of preexisting vector immunity","volume":"16","author":"Holman","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/jmedent\/15.4.307","article-title":"The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa","volume":"15","author":"Hoogstraal","year":"1979","journal-title":"J. Med. Entomol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.antiviral.2012.06.001","article-title":"Molecular biology and genetic diversity of rift valley fever virus","volume":"95","author":"Ikegami","year":"2012","journal-title":"Antiviral Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1080\/14712598.2019.1662784","article-title":"Candidate vaccines for human rift valley fever","volume":"19","author":"Ikegami","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02004-20","article-title":"Development of a simian RNA polymerase I promoter-driven reverse genetics for the rescue of recombinant rift valley fever virus from vero cells","volume":"95","author":"Ikegami","year":"2021","journal-title":"J. Virol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"7262","DOI":"10.1128\/JVI.00135-15","article-title":"Rift valley fever virus MP-12 vaccine is fully attenuated by a combination of partial attenuations in the s, m, and l segments","volume":"89","author":"Ikegami","year":"2015","journal-title":"J. Virol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41541-022-00536-3","article-title":"Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models","volume":"7","author":"Ikegami","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1099\/vir.0.051250-0","article-title":"Rift valley fever virus MP-12 vaccine encoding toscana virus NSs retains neuroinvasiveness in mice","volume":"94","author":"Indran","year":"2013","journal-title":"J. Gen. Virol."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025027","article-title":"Anti-nucleocapsid protein immune responses counteract pathogenic effects of rift valley fever virus infection in mice","volume":"6","author":"Jansen van Vuren","year":"2011","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1016\/S0264-410X(02)00266-9","article-title":"A molecular assembly system that renders antigens of choice highly repetitive for induction of protective b cell responses","volume":"20","author":"Jegerlehner","year":"2002","journal-title":"Vaccine"},{"key":"B70","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1128\/CMR.00062-09","article-title":"A global perspective on hantavirus ecology, epidemiology, and disease","volume":"23","author":"Jonsson","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009973","article-title":"Immune responses in multiple hosts to nucleocapsid protein (NP) of Crimean-Congo hemorrhagic fever virus (CCHFV)","volume":"15","author":"Karaaslan","year":"2021","journal-title":"PloS Negl. Trop. Dis."},{"key":"B72","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4269\/ajtmh.2012.11-0297","article-title":"Isolation and characterization of hantaviruses in far East Russia and etiology of hemorrhagic fever with renal syndrome in the region","volume":"86","author":"Kariwa","year":"2012","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B73","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1093\/oxfordjournals.aje.a113471","article-title":"A rift valley fever vaccine trial. i. side effects and serologic response over a six-month follow-up","volume":"116","author":"Kark","year":"1982","journal-title":"Am. J. Epidemiol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"101693","DOI":"10.1016\/j.mcp.2020.101693","article-title":"Computational formulation and immune dynamics of a multi-peptide vaccine candidate against Crimean-Congo hemorrhagic fever virus","volume":"55","author":"Khan","year":"2021","journal-title":"Mol. Cell Probes"},{"key":"B75","article-title":"Laboratory management of agents associated with hantavirus pulmonary syndrome; interim biosafety guidelines","volume":"43","author":"Knudsen","year":"1994"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1016\/j.vaccine.2012.03.027","article-title":"Efficacy of three candidate rift valley fever vaccines in sheep","volume":"30","author":"Kortekaas","year":"2012","journal-title":"Vaccine"},{"key":"B77","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1089\/vbz.2015.1855","article-title":"Crimean-Congo Hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice","volume":"15","author":"Kortekaas","year":"2015","journal-title":"Vector Borne Zoonotic Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40475-021-00235-4","article-title":"Crimean-Congo Hemorrhagic fever virus (CCHFV): a silent but widespread threat","volume":"8","author":"Kuehnert","year":"2021","journal-title":"Curr. Trop. Med. Rep."},{"key":"B79","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1021\/acsomega.2c07213","article-title":"Current update on rotavirus in-silico multiepitope vaccine design","volume":"8","author":"Kuri","year":"2023","journal-title":"ACS Omega"},{"key":"B80","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1021\/acsabm.1c00426","article-title":"Amphiphilic poly(-vinylpyrrolidone) nanoparticles loaded with DNA plasmids encoding gn and gc glycoproteins of the rift valley fever virus: preparation and evaluation","volume":"4","author":"Kuskov","year":"2021","journal-title":"ACS Appl. Bio Mater."},{"key":"B81","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/infdis\/137.3.298","article-title":"Isolation of the etiologic agent of Korean hemorrhagic fever","volume":"137","author":"Lee","year":"1978","journal-title":"J. Infect. Dis."},{"key":"B82","doi-asserted-by":"publisher","first-page":"104188","DOI":"10.1016\/j.ebiom.2022.104188","article-title":"Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge","volume":"82","author":"Leventhal","year":"2022","journal-title":"EBioMedicine"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2020.00062","article-title":"Immunogenicity assessment of rift valley fever virus virus-like particles in BALB\/c mice","volume":"7","author":"Li","year":"2020","journal-title":"Front. Vet. Sci."},{"key":"B84","doi-asserted-by":"publisher","first-page":"4294","DOI":"10.1016\/j.vaccine.2010.04.025","article-title":"Hantavirus-like particles generated in CHO cells induce specific immune responses in C57BL\/6 mice","volume":"28","author":"Li","year":"2010","journal-title":"Vaccine"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4238\/gmr.15017772","article-title":"Development and characterization of rift valley fever virus-like particles","volume":"15","author":"Li","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1080\/21645515.2016.1253645","article-title":"The assessment of hantaan virus-specific antibody responses after the immunization program for hemorrhagic fever with renal syndrome in northwest China","volume":"13","author":"Li","year":"2017","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1586\/erv.12.106","article-title":"Modifying the NSs gene to improve live-attenuated vaccine for rift valley fever","volume":"11","author":"Lihoradova","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002181","article-title":"Characterization of rift valley fever virus MP-12 strain encoding NSs of punta toro virus or sandfly fever Sicilian virus","volume":"7","author":"Lihoradova","year":"2013","journal-title":"PloS Negl. Trop. Dis."},{"key":"B89","doi-asserted-by":"publisher","first-page":"3445","DOI":"10.1016\/j.vaccine.2018.05.005","article-title":"The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease","volume":"36","author":"Lim","year":"2018","journal-title":"Vaccine"},{"key":"B90","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev-ento-010715-023819","article-title":"Rift valley fever: an emerging mosquito-borne disease","volume":"61","author":"Linthicum","year":"2016","journal-title":"Annu. Rev. Entomol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/S1473-3099(16)30401-7","article-title":"Rift valley fever virus imported into China from Angola","volume":"16","author":"Liu","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B92","doi-asserted-by":"publisher","first-page":"13566","DOI":"10.1128\/JVI.02081-12","article-title":"Genetic subpopulations of rift valley fever virus strains ZH548 and MP-12 and recombinant MP-12 strains","volume":"86","author":"Lokugamage","year":"2012","journal-title":"J. Virol."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002309","article-title":"A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection","volume":"7","author":"L\u00f3pez-Gil","year":"2013","journal-title":"PloS Negl. Trop. Dis."},{"key":"B94","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3390\/vaccines8010082","article-title":"MVA vectored vaccines encoding rift valley fever virus glycoproteins protect mice against lethal challenge in the absence of neutralizing antibody responses","volume":"8","author":"L\u00f3pez-Gil","year":"2020","journal-title":"Vaccines"},{"key":"B95","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13567-018-0516-z","article-title":"Efficacy of different DNA and MVA prime-boost vaccination regimens against a rift valley fever virus (RVFV) challenge in sheep 12 weeks following vaccination","volume":"49","author":"Lorenzo","year":"2018","journal-title":"Vet. Res."},{"key":"B96","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1016\/j.vaccine.2010.02.018","article-title":"Protection against lethal rift valley fever virus (RVFV) infection in transgenic IFNAR(-\/-) mice induced by different DNA vaccination regimens","volume":"28","author":"Lorenzo","year":"2010","journal-title":"Vaccine"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0185194","article-title":"Risk analysis of inter-species reassortment through a rift valley fever phlebovirus MP-12 vaccine strain","volume":"12","author":"Ly","year":"2017","journal-title":"PloS One"},{"key":"B98","doi-asserted-by":"publisher","first-page":"6634","DOI":"10.1016\/j.vaccine.2017.10.036","article-title":"Attenuation and protective efficacy of rift valley fever phlebovirus rMP12-GM50 strain","volume":"35","author":"Ly","year":"2017","journal-title":"Vaccine"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1080\/21645515.2019.1627820","article-title":"In vitro and in vivo efficacy of a rift valley fever virus vaccine based on pseudovirus","volume":"15","author":"Ma","year":"2019","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"B100","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12985-020-01421-y","article-title":"Protective CD8 T-cell response against hantaan virus infection induced by immunization with designed linear multi-epitope peptides in HLA-A2.1\/K transgenic mice","volume":"17","author":"Ma","year":"2020","journal-title":"Virol. J."},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0004550","article-title":"Rift valley fever vaccine virus clone 13 is able to cross the ovine placental barrier associated with foetal infections, malformations, and stillbirths","volume":"10","author":"Makoschey","year":"2016","journal-title":"PloS Negl. Trop. Dis."},{"key":"B102","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41541-021-00352-1","article-title":"A single dose of replication-competent VSV-vectored vaccine expressing SARS-CoV-2 S1 protects against virus replication in a hamster model of severe COVID-19","volume":"6","author":"Malherbe","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.1021\/acs.chemrev.9b00472","article-title":"Peptide-based vaccines: current progress and future challenges","volume":"120","author":"Malonis","year":"2020","journal-title":"Chem. Rev."},{"key":"B104","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.virol.2009.11.001","article-title":"A replication-incompetent rift valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challenge","volume":"397","author":"Mandell","year":"2010","journal-title":"Virology"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1002\/biot.201800238","article-title":"Chimaeric rift valley fever virus-like particle vaccine candidate production in nicotiana benthamiana","volume":"14","author":"Mbewana","year":"2019","journal-title":"Biotechnol. J."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01394-19","article-title":"Rift valley fever: a threat to pregnant women hiding in plain sight","volume":"95","author":"McMillen","year":"2021","journal-title":"J. Virol."},{"key":"B107","article-title":"Biosafety in microbiological and biomedical laboratories","author":"Meechan","year":"2020"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.10.062","article-title":"Rift valley fever MP-12 vaccine elicits an early protective immune response in mice","volume":"40","author":"Morrill","year":"2022","journal-title":"Vaccine"},{"key":"B109","doi-asserted-by":"publisher","first-page":"6225","DOI":"10.1016\/j.vaccine.2012.08.003","article-title":"Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine","volume":"30","author":"Mousavi-Jazi","year":"2012","journal-title":"Vaccine"},{"key":"B110","doi-asserted-by":"publisher","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of rift valley fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002746","article-title":"Development of a novel, single-cycle replicable rift valley fever vaccine","volume":"8","author":"Murakami","year":"2014","journal-title":"PloS Negl. Trop. Dis."},{"key":"B112","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3109\/inf.1982.14.issue-2.06","article-title":"Rift valley fever virus vaccine trial: study of side-effects in humans","volume":"14","author":"Niklasson","year":"1982","journal-title":"Scand. J. Infect. Dis."},{"key":"B113","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1128\/JVI.02241-15","article-title":"The l, m, and s segments of rift valley fever virus MP-12 vaccine independently contribute to a temperature-sensitive phenotype","volume":"90","author":"Nishiyama","year":"2016","journal-title":"J. Virol."},{"key":"B114","doi-asserted-by":"publisher","first-page":"103160","DOI":"10.1016\/j.jbi.2019.103160","article-title":"Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: a computer-aided vaccine design approach","volume":"93","author":"Nosrati","year":"2019","journal-title":"J. BioMed. Inform"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2017.00213","article-title":"Crimean-Congo Hemorrhagic fever: tick-Host-Virus interactions","volume":"7","author":"Papa","year":"2017","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B116","doi-asserted-by":"publisher","first-page":"14926","DOI":"10.1073\/pnas.1112149108","article-title":"Recombinant rift valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice","volume":"108","author":"Papin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008834","article-title":"Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model","volume":"14","author":"Pavel","year":"2020","journal-title":"PloS Negl. Trop. Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00705-017-3315-3","article-title":"Expression and characterization of codon-optimized Crimean-Congo hemorrhagic fever virus gn glycoprotein in insect cells","volume":"162","author":"Rahpeyma","year":"2017","journal-title":"Arch. Virol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"660","DOI":"10.4049\/jimmunol.89.5.660","article-title":"The development of a formalin-killed rift valley fever virus vaccine for use in man","volume":"89","author":"Randall","year":"1962","journal-title":"J. Immunol."},{"key":"B120","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1017\/S0950268813002987","article-title":"Detection of IgG antibody against Crimean-Congo haemorrhagic fever virus using ELISA with recombinant nucleoprotein antigens from genetically diverse strains","volume":"142","author":"Rangunwala","year":"2014","journal-title":"Epidemiol. Infect."},{"key":"B121","volume-title":"Biosafety in microbiological and biomedical laboratories","author":"Richmond","year":"2009"},{"key":"B122","doi-asserted-by":"publisher","first-page":"7755","DOI":"10.1038\/s41598-019-44210-6","article-title":"Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever","volume":"9","author":"Rodriguez","year":"2019","journal-title":"Sci. Rep."},{"key":"B123","doi-asserted-by":"publisher","first-page":"105244","DOI":"10.1016\/j.antiviral.2022.105244","article-title":"Immunobiology of Crimean-Congo hemorrhagic fever","volume":"199","author":"Rodriguez","year":"2022","journal-title":"Antiviral Res."},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2013.81","article-title":"The risk of rift valley fever virus introduction and establishment in the united states and European union","volume":"2","author":"Rolin","year":"2013","journal-title":"Emerg. Microbes Infect."},{"key":"B125","doi-asserted-by":"publisher","first-page":"106498","DOI":"10.1016\/j.actatropica.2022.106498","article-title":"Immunogenicity and safety studies of an inactivated vaccine against rift valley fever","volume":"232","author":"Ronchi","year":"2022","journal-title":"Acta Trop."},{"key":"B126","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1186\/s12967-016-1084-5","article-title":"BoHV-4-based vector delivering Ebola virus surface glycoprotein","volume":"14","author":"Rosamilia","year":"2016","journal-title":"J. Transl. Med."},{"key":"B127","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.virusres.2011.10.023","article-title":"Animal models of rift valley fever virus infection","volume":"163","author":"Ross","year":"2012","journal-title":"Virus Res."},{"key":"B128","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12985-017-0811-8","article-title":"An equine herpesvirus type 1 (EHV-1) vector expressing rift valley fever virus (RVFV) gn and gc induces neutralizing antibodies in sheep","volume":"14","author":"Said","year":"2017","journal-title":"Virol. J."},{"key":"B129","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/j.sjbs.2021.12.004","article-title":"Development of multivalent vaccine targeting m segment of Crimean Congo hemorrhagic fever virus (CCHFV) using immunoinformatic approaches","volume":"29","author":"Sana","year":"2022","journal-title":"Saudi J. Biol. Sci."},{"key":"B130","doi-asserted-by":"publisher","first-page":"7263","DOI":"10.1128\/JVI.76.14.7263-7275.2002","article-title":"Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus","volume":"76","author":"Sanchez","year":"2002","journal-title":"J. Virol."},{"key":"B131","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4161\/hv.2.2.2620","article-title":"Preclinical and clinical safety studies on DNA vaccines","volume":"2","author":"Schalk","year":"2006","journal-title":"Hum. Vaccin."},{"key":"B132","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/22221751.2019.1601030","article-title":"Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice","volume":"8","author":"Scholte","year":"2019","journal-title":"Emerg. Microbes Infect."},{"key":"B133","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10529-020-02816-1","article-title":"Microencapsulated plasmids expressing gn and gc glycoproteins of rift valley fever virus enhance humoral immune response in mice","volume":"42","author":"Selina","year":"2020","journal-title":"Biotechnol. Lett."},{"key":"B134","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.virusres.2011.10.016","article-title":"Infection of hantaan virus strain AA57 leading to pulmonary disease in laboratory mice","volume":"163","author":"Seto","year":"2012","journal-title":"Virus Res."},{"key":"B135","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.virol.2009.02.038","article-title":"Single-particle cryo-electron microscopy of rift valley fever virus","volume":"387","author":"Sherman","year":"2009","journal-title":"Virology"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s11427-017-9211-0","article-title":"Pathogen genomic surveillance elucidates the origins, transmission and evolution of emerging viral agents in China","volume":"60","author":"Shi","year":"2017","journal-title":"Sci. China Life Sci."},{"key":"B137","doi-asserted-by":"publisher","first-page":"14699","DOI":"10.1038\/s41598-021-93319-0","article-title":"Development of double antibody sandwich ELISA as potential diagnostic tool for rapid detection of Crimean-Congo hemorrhagic fever virus","volume":"11","author":"Shrivastava","year":"2021","journal-title":"Sci. Rep."},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004390","article-title":"Crimean-Congo Hemorrhagic fever virus entry into host cells occurs through the multivesicular body and requires ESCRT regulators","volume":"10","author":"Shtanko","year":"2014","journal-title":"PloS Pathog."},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fvets.2021.779858","article-title":"Safety, immunogenicity and antibody persistence of rift valley fever virus clone 13 vaccine in sheep, goats and cattle in Tanzania","volume":"8","author":"Sindato","year":"2021","journal-title":"Front. Vet. Sci."},{"key":"B140","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1128\/JVI.06190-11","article-title":"Development of a novel nonhuman primate model for rift valley fever","volume":"86","author":"Smith","year":"2012","journal-title":"J. Virol."},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006474","article-title":"Attenuation and efficacy of live-attenuated rift valley fever virus vaccine candidates in non-human primates","volume":"12","author":"Smith","year":"2018","journal-title":"PloS Negl. Trop. Dis."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1128\/CVI.00220-10","article-title":"Protection of sheep against rift valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine","volume":"17","author":"Soi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"B143","doi-asserted-by":"publisher","first-page":"8016","DOI":"10.1016\/j.vaccine.2020.10.035","article-title":"Immunogenicity and safety of a modified three-dose priming and booster schedule for the hantaan virus vaccine (Hantavax): a multi-center phase III clinical trial in healthy adults","volume":"38","author":"Song","year":"2020","journal-title":"Vaccine"},{"key":"B144","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.vaccine.2016.01.031","article-title":"Long-term immunogenicity and safety of inactivated hantaan virus vaccine (Hantavax\u2122) in healthy adults","volume":"34","author":"Song","year":"2016","journal-title":"Vaccine"},{"key":"B145","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.antiviral.2016.09.013","article-title":"A chronological review of experimental infection studies of the role of wild animals and livestock in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus","volume":"135","author":"Spengler","year":"2016","journal-title":"Antiviral Res."},{"key":"B146","doi-asserted-by":"publisher","first-page":"105090","DOI":"10.1016\/j.antiviral.2021.105090","article-title":"Viral replicon particles protect IFNAR mice against lethal Crimean-Congo hemorrhagic fever virus challenge three days after vaccination","volume":"191","author":"Spengler","year":"2021","journal-title":"Antiviral Res."},{"key":"B147","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41541-019-0138-0","article-title":"Safety and efficacy of ChAdOx1 RVF vaccine against rift valley fever in pregnant sheep and goats","volume":"4","author":"Stedman","year":"2019","journal-title":"NPJ Vaccines"},{"key":"B148","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1007\/s00705-016-2803-1","article-title":"Analysis of the entry mechanism of Crimean-Congo hemorrhagic fever virus, using a vesicular stomatitis virus pseudotyping system","volume":"161","author":"Suda","year":"2016","journal-title":"Arch. Virol."},{"key":"B149","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based Ebola virus vaccine: from concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum. Vaccines Immunotherapeutics"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01797","article-title":"Novel identified HLA-A*0201-Restricted hantaan virus glycoprotein cytotoxic T-cell epitopes could effectively induce protective responses in HLA-A2.1\/K transgenic mice may associate with the severity of hemorrhagic fever with renal syndrome","volume":"8","author":"Tang","year":"2017","journal-title":"Front. Immunol."},{"key":"B151","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s10544-023-00649-z","article-title":"Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions","volume":"25","author":"Tarim","year":"2023","journal-title":"BioMed. Microdevices"},{"key":"B152","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.4269\/ajtmh.20-1413","article-title":"Epidemiology of Crimean-Congo hemorrhagic fever (CCHF) in Africa-underestimated for decades","volume":"104","author":"Temur","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B153","doi-asserted-by":"publisher","first-page":"17097","DOI":"10.1038\/s41598-018-35472-7","article-title":"A single-cycle replicable rift valley fever phlebovirus vaccine carrying a mutated NSs confers full protection from lethal challenge in mice","volume":"8","author":"Terasaki","year":"2018","journal-title":"Sci. Rep."},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2039","article-title":"Structural and functional similarities in bunyaviruses: perspectives for pan-bunya antivirals","volume":"29","author":"Ter Horst","year":"2019","journal-title":"Rev. Med. Virol."},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006901","article-title":"The ecological dynamics of hantavirus diseases: from environmental variability to disease prevention largely based on data from China","volume":"13","author":"Tian","year":"2019","journal-title":"PloS Negl. Trop. Dis."},{"key":"B156","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.3390\/vaccines9121491","article-title":"Immunogenicity of a DNA-based sindbis replicon expressing Crimean-Congo hemorrhagic fever virus nucleoprotein","volume":"9","author":"Tipih","year":"2021","journal-title":"Vaccines"},{"key":"B157","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3390\/pathogens11020233","article-title":"Enhanced seroconversion to West Nile virus proteins in mice by West Nile kunjin replicon virus-like particles expressing glycoproteins from Crimean-Congo hemorrhagic fever virus","volume":"11","author":"Tran","year":"2022","journal-title":"Pathogens"},{"key":"B158","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jhin.2019.12.001","article-title":"Nosocomial infections caused by Crimean-Congo haemorrhagic fever virus","volume":"105","author":"Tsergouli","year":"2020","journal-title":"J. Hosp. Infect."},{"key":"B159","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"von Krempelhuber","year":"2010","journal-title":"Vaccine"},{"key":"B160","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3390\/microorganisms9020438","article-title":"Phylogenetic characterization of Crimean-Congo hemorrhagic fever virus detected in African blue ticks feeding on cattle in a Ugandan abattoir","volume":"9","author":"Wampande","year":"2021","journal-title":"Microorganisms"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41564-019-0411-z","article-title":"Neutralization mechanism of human monoclonal antibodies against rift valley fever virus","volume":"4","author":"Wang","year":"2019","journal-title":"Nat. Microbiol."},{"key":"B162","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.3390\/v14081664","article-title":"GEM-PA-Based subunit vaccines of Crimean Congo hemorrhagic fever induces systemic immune responses in mice","volume":"14","author":"Wang","year":"2022","journal-title":"Viruses"},{"key":"B163","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/1743-422X-10-349","article-title":"Immunogenicity and efficacy of a chimpanzee adenovirus-vectored rift valley fever vaccine in mice","volume":"10","author":"Warimwe","year":"2013","journal-title":"Virol. J."},{"key":"B164","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.antiviral.2009.10.008","article-title":"Present and future arboviral threats","volume":"85","author":"Weaver","year":"2010","journal-title":"Antiviral Res."},{"key":"B165","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.3390\/v14102247","article-title":"Pathological studies on hantaan virus-infected mice simulating severe hemorrhagic fever with renal syndrome","volume":"14","author":"Wei","year":"2022","journal-title":"Viruses"},{"key":"B166","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1016\/j.vaccine.2013.12.064","article-title":"Efficacy of a recombinant rift valley fever virus MP-12 with NSm deletion as a vaccine candidate in sheep","volume":"32","author":"Weingartl","year":"2014","journal-title":"Vaccine"},{"key":"B167","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41541-022-00476-y","article-title":"Safety and immunogenicity of four-segmented rift valley fever virus in the common marmoset","volume":"7","author":"Wichgers Schreur","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B168","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1099\/vir.0.067660-0","article-title":"Paramyxovirus-based production of rift valley fever virus replicon particles","volume":"95","author":"Wichgers Schreur","year":"2014","journal-title":"J. Gen. Virol."},{"key":"B169","doi-asserted-by":"publisher","first-page":"10883","DOI":"10.1128\/JVI.00961-14","article-title":"Creation of rift valley fever viruses with four-segmented genomes reveals flexibility in bunyavirus genome packaging","volume":"88","author":"Wichgers Schreur","year":"2014","journal-title":"J. Virol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41541-020-00271-7","article-title":"A single vaccination with four-segmented rift valley fever virus prevents vertical transmission of the wild-type virus in pregnant ewes","volume":"6","author":"Wichgers Schreur","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B171","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3390\/vaccines9030301","article-title":"Vaccine efficacy of self-assembled multimeric protein scaffold particles displaying the glycoprotein gn head domain of rift valley fever virus","volume":"9","author":"Wichgers Schreur","year":"2021","journal-title":"Vaccines"},{"key":"B172","doi-asserted-by":"publisher","first-page":"8890","DOI":"10.1128\/JVI.76.17.8890-8899.2002","article-title":"Hantaan virus infection causes an acute neurological disease that is fatal in adult laboratory mice","volume":"76","author":"Wichmann","year":"2002","journal-title":"J. Virol."},{"key":"B173","doi-asserted-by":"publisher","first-page":"748","DOI":"10.3390\/vaccines9070748","article-title":"Preliminary evaluation of a recombinant rift valley fever virus glycoprotein subunit vaccine providing full protection against heterologous virulent challenge in cattle","volume":"9","author":"Wilson","year":"2021","journal-title":"Vaccines"},{"key":"B174","doi-asserted-by":"publisher","first-page":"13335","DOI":"10.1128\/JVI.01238-07","article-title":"NSm protein of rift valley fever virus suppresses virus-induced apoptosis","volume":"81","author":"Won","year":"2007","journal-title":"J. Virol."},{"key":"B175","doi-asserted-by":"publisher","first-page":"E7564","DOI":"10.1073\/pnas.1705176114","article-title":"Structures of phlebovirus glycoprotein gn and identification of a neutralizing antibody epitope","volume":"114","author":"Wu","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B176","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.virusres.2013.01.008","article-title":"Infection and propagation of Crimean-Congo hemorrhagic fever virus in embryonated chicken eggs","volume":"173","author":"Xia","year":"2013","journal-title":"Virus Res."},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0059210","article-title":"The nucleocapsid protein of rift valley fever virus is a potent human CD8+ T cell antigen and elicits memory responses","volume":"8","author":"Xu","year":"2013","journal-title":"PloS One"},{"key":"B178","doi-asserted-by":"publisher","first-page":"100306","DOI":"10.1016\/j.xinn.2022.100306","article-title":"Co-Existence and co-infection of influenza a viruses and coronaviruses: public health challenges","volume":"3","author":"Yang","year":"2022","journal-title":"Innovation (Camb.)"},{"key":"B179","doi-asserted-by":"publisher","first-page":"63488","DOI":"10.18632\/oncotarget.11329","article-title":"Construction and immunological characterization of CD40L or GM-CSF incorporated hantaan virus like particle","volume":"7","author":"Ying","year":"2016","journal-title":"Oncotarget"},{"key":"B180","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2020.07.024","article-title":"A thermostable mRNA vaccine against COVID-19","volume":"182","author":"Zhang","year":"2020","journal-title":"Cell"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.799942","article-title":"Bacterium-like particles displaying the rift valley fever virus gn head protein induces efficacious immune responses in immunized mice","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Microbiol."},{"key":"B182","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12250-011-3209-6","article-title":"Production of CCHF virus-like particle by a baculovirus-insect cell expression system","volume":"26","author":"Zhou","year":"2011","journal-title":"Virol. Sin."},{"key":"B183","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.antiviral.2017.08.014","article-title":"Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus","volume":"146","author":"Zivcec","year":"2017","journal-title":"Antiviral Res."},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006628","article-title":"Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge","volume":"12","author":"Zivcec","year":"2018","journal-title":"PloS Negl. Trop. Dis."},{"key":"B185","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/jhep.2001.27564","article-title":"Evaluation of a new hepatitis b triple-antigen vaccine in inadequate responders to current vaccines","volume":"34","author":"Zuckerman","year":"2001","journal-title":"Hepatology"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1174030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T07:23:11Z","timestamp":1684394591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2023.1174030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,18]]},"references-count":185,"alternative-id":["10.3389\/fcimb.2023.1174030"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2023.1174030","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,18]]},"article-number":"1174030"}}